Frontiers in medicine · 2026
Elevated TFR1 is associated with inflammatory burden and ferroptosis in ulcerative colitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Xiaotong, Ji Jieru, Feng Lingmei, Chen Guoyu, Yao Yao
Аннотация
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal inflammation, oxidative stress, and iron metabolism dysregulation. Ferroptosis, an iron-dependent form of regulated cell death, may contribute to the pathogenesis of UC. Transferrin receptor 1 (TFR1), a key mediator of cellular iron uptake, links iron dysregulation to inflammation and ferroptosis; however, its clinical relevance in UC is not well defined.
METHODS: Serum samples were collected from 83 patients with active UC and 80 age- and sex-matched healthy controls. Disease activity was assessed using the modified Mayo score. Serum TFR1, inflammatory cytokine, coagulation indices, oxidative stress marker, and ferroptosis-related antioxidant levels were measured. Correlations and receiver operating characteristic (ROC) curve analyses were performed to evaluate the associations and diagnostic performance.
RESULTS: Serum TFR1 levels were significantly higher in patients with UC than in controls (p < 0.001) and increased progressively with disease severity. TFR1 showed positive correlations with the Mayo score (r = 0.510), inflammatory markers, including C-reactive protein (CRP; r = 0.350), tumor necrosis factor-alpha (TNF-α; r = 0.406), interleukin-1 beta (IL-1β; r = 0.471), and interleukin-6 (IL-6; r = 0.432), coagulation parameters, including platelet count (r = 0.225), erythrocyte sedimentation rate (ESR; r = 0.451), and D-dimer (r = 0.447), serum iron (r = 0.267), and lipid peroxidation (r = 0.315), and negative correlations with the antioxidant defenses glutathione peroxidase 4 (GPX4; r = -0.236) and glutathione (GSH; r = -0.302). ROC analysis demonstrated that serum TFR1 distinguished patients with UC from controls, with an AUC of 0.795 at a cutoff of 4.8 ng/mL.
CONCLUSION: Elevated serum TFR1 levels are associated with UC severity, systemic inflammation, oxidative stress, and ferroptosis-related imbalance. These findings suggest that TFR1 is a potential biomarker for UC activity and highlight iron-driven ferroptosis as a promising therapeutic target, providing novel clinical insights into disease monitoring and management.
METHODS: Serum samples were collected from 83 patients with active UC and 80 age- and sex-matched healthy controls. Disease activity was assessed using the modified Mayo score. Serum TFR1, inflammatory cytokine, coagulation indices, oxidative stress marker, and ferroptosis-related antioxidant levels were measured. Correlations and receiver operating characteristic (ROC) curve analyses were performed to evaluate the associations and diagnostic performance.
RESULTS: Serum TFR1 levels were significantly higher in patients with UC than in controls (p < 0.001) and increased progressively with disease severity. TFR1 showed positive correlations with the Mayo score (r = 0.510), inflammatory markers, including C-reactive protein (CRP; r = 0.350), tumor necrosis factor-alpha (TNF-α; r = 0.406), interleukin-1 beta (IL-1β; r = 0.471), and interleukin-6 (IL-6; r = 0.432), coagulation parameters, including platelet count (r = 0.225), erythrocyte sedimentation rate (ESR; r = 0.451), and D-dimer (r = 0.447), serum iron (r = 0.267), and lipid peroxidation (r = 0.315), and negative correlations with the antioxidant defenses glutathione peroxidase 4 (GPX4; r = -0.236) and glutathione (GSH; r = -0.302). ROC analysis demonstrated that serum TFR1 distinguished patients with UC from controls, with an AUC of 0.795 at a cutoff of 4.8 ng/mL.
CONCLUSION: Elevated serum TFR1 levels are associated with UC severity, systemic inflammation, oxidative stress, and ferroptosis-related imbalance. These findings suggest that TFR1 is a potential biomarker for UC activity and highlight iron-driven ferroptosis as a promising therapeutic target, providing novel clinical insights into disease monitoring and management.